Navigation Links
Savient Pharmaceuticals Provides Business Update
Date:1/7/2011

EAST BRUNSWICK, N.J., Jan. 7, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today provided an update on its business activities related to the U.S. launch and commercialization of KRYSTEXXA, a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.  Savient continues to believe that it is on track for the promotional launch of KRYSTEXXA in the first quarter of 2011.  

The Company announced that:

  • KRYSTEXXA became commercially available in the U.S. by prescription on December 1, 2010 with the commencement of sales and shipments by the Company to its network of specialty distributors and to its wholesale distributors.
  • The first chronic gout patient received treatment with KRYSTEXXA in December.
  • The Company has built out much of its planned sales, marketing, managed care, medical affairs and pharmacovigilance teams, including hiring the full team of six regional business directors and more than 60% of the planned territory sales representatives.  As a group, these hires bring additional rheumatology and biologics experience to Savient's commercial team.
  • In early December, the Company activated its pharmacovigilance hotline and comprehensive reimbursement support services hotline and internet portal through its third party service providers PPD and Covance.
  • To date, several large private managed care organizations have added medical benefits coverage for KRYSTEXXA, and others are actively evaluating medical benefits coverage.  The Company has also filed for a temporary "C" code and a permanent "J" code application with the Centers for Medicare & Medicaid Services in December of 2010.
  • In support of the commercial launch of KRYSTEXXA, the Company has in inventory at its third party
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
11. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 Researchers from the Southern ... between lower back pain, and the acne causing P.acnes bacteria. ... system the bacteria seek out oxygen deprived location to seek ... spinal column, P.acnes has the ability to live in the ... Perez, a spokesman for “ The best acne treatment ” ...
(Date:5/20/2013)... Kitware, a leader in data visualization, today unveils ... exploration of hospital costs across the United States . ... release of “Medicare Provider Charge Data,” a dataset of ... the Centers for Medicare & Medicaid Services. , The ... across the country has sparked considerable controversy; however, it ...
(Date:5/19/2013)... York, NY (PRWEB) May 19, 2013 ... solar boat, today announced a new speed record for ... left from Las Palmas, Spain, on April 25, 2013, ... the Atlantic Ocean at the average speed of 5.3 ... West Indies on May 18, 2013. The first-of-its-kind catamaran ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine and ... Albert Einstein College of Medicine and Associate Chairman of ... He is also Associate Director for Clinical Research ... Breast Cancer Working Group, a multidisciplinary group of physicians ... also serves as Vice Chair of the National Cancer ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2Kitware Enables Interactive Exploration of CMS Medicare Data 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced the schedule of its upcoming Contrave® (naltrexone sustained ... Annual Scientific Meeting of The Obesity Society. This meeting ... October 8-12, 2010.Sunday, October 10:  Embargo Lifts October 10 ...
... caprotec bioanalytics GmbH announced today the appointment of ... Officer and Chief Operating Officer of the company.  Prior ... at Merck & Co., Schering AG and Novartis. ... leader in the global pharmaceutical industry," said caprotec founder ...
... RHHBY) announced today that the cobas ® TaqScreen DPX Test ... now available with the CE Mark. It is the first IVD ... B19 (B19V) and hepatitis A virus (HAV) in one assay. The ... which simultaneously quantifies B19V genotypes 1, 2 and 3 DNA and ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2caprotec bioanalytics GmbH Appoints Prof. Dr. Rainer Metternich as Managing Director, Chief Business Officer and Chief Operating Officer 2First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products 2First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products 3
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
(Date:5/16/2013)... fast food restaurant had a higher body mass index ... food, according to researchers at The University of Texas ... strong among those with a lower income. , ... Journal of Public Health indicates higher BMI associates ... among lower-income African-Americans, the density, or number, of fast ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... in Alaska's tundra, and a corresponding northward progression of the ... of warmer and longer summers in the Alaskan Arctic according ... 22, 2005, issue of Science Express. , The resulting atmospheric ... what might be observed if there was a doubling of ...
... at blink-of-the-eye speeds by squirting chemicals called neurotransmitters across ... lots of different receptors and neurotransmitters work simultaneously. Which ... reported in the July 20 issue of the Journal ... led by David Featherstone, a University of Illinois at ...
... is detected is a defensive, protective reaction. This ancestral ... by a potential predator. A new study published in ... freeze when encountering a threat. The mere picture of ... viewing these unpleasant images, the study's participants froze as ...
Cached Biology News:Lands surface change on Alaska tundra creating longer, warmer summers in Arctic 2UIC researchers show protein routes messages in nerve cells 2When in danger humans are similar to a deer in the headlights 2
... LC Sciences provides a genome-wide microRNA (miRNA) ... proprietary probe design, which enable highly sensitive ... We have standard arrays for mature miRNA ... version of the Sanger miRBase database (Release ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... Custom peptide microarrays designed for quantitative ... samples and built on the flexible ... Thousands of customer specified sequences can ... can provide assistance with custom sequence ...
... Now, for the first time, you can ... and more efficiently without interferences. The Agilent ... remove unwanted, multiple high-abundant proteins from human ... with just one device. With this revolutionary ...
Biology Products: